Both monotherapies suppressed tumor growth, yet the combination regimen achieved superior efficacy, suggesting additive antitumor effects (Control: 617.93 ± 118.01 mm3; UK122: 257.78 ± 71.54 mm3; anti-PD-1: 353.77 ± 167.47 mm3; combination: 100.16 ± 49.79 mm3, Figures 7B, C). The gene discussed is PDCD1; the disease is neoplasm.